エピソード

  • 13: Enfortumab Vedotin and the Evolving Landscape of Bladder Cancer Care: A Pharmacist’s Guide to ADCs, Combination Therapy, and Expanding Clinical Engagement

    13: Enfortumab Vedotin and the Evolving Landscape of Bladder Cancer Care: A Pharmacist’s Guide to ADCs, Combination Therapy, and Expanding Clinical Engagement
    2026/05/19
    A landscape overview of enfortumab vedotin’s expanding role across bladder cancer settings — from MIBC to earlier lines of therapy — with a focus on pharmacist-led patient support, AE management, and real-world implementation.
    続きを読む 一部表示
    51 分
  • 10: Clinical Approaches for Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

    10: Clinical Approaches for Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer
    2026/05/01
    This episode reviews treatment intensification in metastatic castration-sensitive prostate cancer, focusing on why ADT plus an ARPI is the current backbone of care, what barriers still limit its use, and how clinicians think about triplet therapy, de-intensification, frail patients, and emerging biomarker-driven options such as PARP inhibitors.
    続きを読む 一部表示
    34 分
  • 9: Indirect Trial Comparisons in Metastatic Castration-Sensitive Prostate Cancer

    9: Indirect Trial Comparisons in Metastatic Castration-Sensitive Prostate Cancer
    2026/05/01
    This episode examines how indirect trial comparisons can help guide ARPI selection in metastatic castration-sensitive prostate cancer when head-to-head studies are unavailable, while emphasizing the importance of patient-specific factors, tolerability, and clinical judgment.
    続きを読む 一部表示
    34 分
  • 8: Personalizing Long-Term Treatment of Metastatic Castration-Sensitive Prostate Cancer

    8: Personalizing Long-Term Treatment of Metastatic Castration-Sensitive Prostate Cancer
    2026/05/01
    This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient fitness, quality of life, and shared decision-making.
    続きを読む 一部表示
    33 分
  • 7: Managing Fatigue with ARPIs in Metastatic Castration-Sensitive Prostate Cancer in the Clinic

    7: Managing Fatigue with ARPIs in Metastatic Castration-Sensitive Prostate Cancer in the Clinic
    2026/05/01
    This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
    続きを読む 一部表示
    31 分
  • 12: Monotherapies for Treatment of High-Risk Biochemical Recurrent Prostate Cancer

    12: Monotherapies for Treatment of High-Risk Biochemical Recurrent Prostate Cancer
    2026/04/01
    The faculty discusses how ARPI monotherapy may fit into the management of high-risk biochemically recurrent prostate cancer, with a focus on patient selection, trade-offs of monotherapy versus combination therapy, and practical counseling around efficacy, quality of life, and adverse events. The conversation also explores emerging questions around biomarkers, PARP inhibitors, treatment intensification, and how monotherapy may evolve as a therapeutic option in select patients.
    続きを読む 一部表示
    29 分
  • 11: Treatment Strategies with Androgen Receptor Pathway Inhibitors in Castration-Sensitive Prostate Cancer

    11: Treatment Strategies with Androgen Receptor Pathway Inhibitors in Castration-Sensitive Prostate Cancer
    2026/04/01
    The faculty discuss how androgen receptor pathway inhibitor–based strategies are reshaping the management of high-risk biochemical recurrence, with an emphasis on risk stratification, imaging, and patient selection for systemic therapy. The conversation also explores how long-term clinical evidence, treatment suspension, and emerging study designs are informing more individualized treatment decisions in practice.
    続きを読む 一部表示
    35 分
  • 7: Test File

    7: Test File
    2026/03/18
    33 分